April 21, 2021: “Novo Nordisk announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg.
The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg.
Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 1,000 people with obesity or overweight with comorbidities. The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo.
Related News: Novo-Nordisk’s semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in 68-week trial
Novo Nordisk’s wins big obesity ambitions take shape with semaglutide
Novo Nordisk invests DKK 500 million in expanding tablet production facilities in Denmark
“There is a significant unmet medical need within obesity treatment today.
With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk.
“As a complement to our injectable anti-obesity medications, oral semaglutide has the potential to help more people living with obesity achieve weight loss goals and improve their health.”